Outcomes20

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 20

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12	Baseline and Visit 8 Which Spans Weeks 11/12	The Full Analysis Set was defined as all randomized subjects who took at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment (i.e., number of binge days per week calculated for at least 1 week).	Binge days per week	LEAST_SQUARES_MEAN
SECONDARY	Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores	Up to 12 weeks	Full Analysis Set	percentage of participants	NUMBER
SECONDARY	Percent of Participants With a 4-Week Cessation From Binge Eating	Up to 12 weeks	Full Analysis Set	percentage of participants	NUMBER
SECONDARY	Percent Change From Baseline in Body Weight (kg) at Week 12	Baseline and week 12	Full Analysis Set.	percentage change	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12	Baseline and week 12	Full Analysis Set.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks	Baseline and up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	mmol/L	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks	Baseline and up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	mmol/L	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks	Baseline and up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	Percent	LEAST_SQUARES_MEAN
SECONDARY	Binge Eating Response	Up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	percentage of participants	NUMBER
SECONDARY	Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 Which Spans Weeks 11/12	Baseline and Visit 8 Which Spans Weeks 11/12	Full Analysis Set.	Binge episodes per week	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Eating Inventory Scores at Week 12	Baseline and week 12	Full Analysis Set.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Binge Eating Scale (BES) Score at Week 12	Baseline and week 12	Full Analysis Set.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Up to 12 Weeks	Baseline and up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	t-scores	LEAST_SQUARES_MEAN
SECONDARY	EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility	Up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	percentage of participants	NUMBER
SECONDARY	EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care	Up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	percentage of participants	NUMBER
SECONDARY	EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities	Up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	percentage of participants	NUMBER
SECONDARY	EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort	Up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	percentage of participants	NUMBER
SECONDARY	EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression	Up to 12 weeks	Full Analysis Set. Not all subjects had data for this outcome.	percentage of participants	NUMBER
SECONDARY	Columbia-Suicide Severity Rating Scale (C-SSRS)	Up to 12 weeks	For this Outcome Measure the Safety Analysis Set is defined as all randomized subjects who took at least 1 dose of investigational product and who had at least 1 post-baseline safety assessment completed, and responded to the relevant questions for the C-SSRS. All subjects from Site 015 were excluded from the Safety Analysis Set.	participants	NUMBER
SECONDARY	Change in Amphetamine Cessation Symptom Assessment (ACSA) Total Score From Baseline to Week 12.	Baseline and Week 12	Safety Analysis Set who completed ACSC at Baseline \& Week 12 Visits.	units on a scale	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01718509/outcomes

API reference For AI assistants